FDA Approves Supplemental New Drug Application (sNDA) for Boehringer Ingelheim’s STIOLTO® RESPIMAT® (tiotropium bromide and olodaterol) Inhalation Spray for COPD Health-Related Quality of Life
Source: Boehringer Ingelheim Press Releases - Category: Research Source Type: news
More News: Chronic Obstructive Pulmonary | Health | New Drug Applications | Research | Spiriva | Tiotropium